Triple-Negative Breast Cancer

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

By MedXY 12/09/2025

A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated in premenopausal women; hematologic toxicity increased.

news Oncology

Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits

By MedXY 11/30/2025

A 10‑year follow‑up of SYSUCC‑001 shows 1 year of metronomic capecitabine after standard adjuvant therapy improved disease‑free survival in early triple‑negative breast cancer; FOXC1 expression emerged as a potential predictive biomarker in exploratory analyses.

OB/GYN & Women's Health Oncology

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

By MedXY 10/24/2025

This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.

Clinical Updates Family Medicine & Nutrition news Oncology Specialties

The Dark Side of Olive Oil: High-Oil Diets Promote Lung Metastasis in Triple-Negative Breast Cancer

By MedXY 09/16/2025

Recent research reveals that high-fat diets rich in olive oil, while not impairing immunity, significantly promote lung metastasis of triple-negative breast cancer via a novel fatty acid-driven mechanism involving FABP5 and ALDH pathways.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer

By MedXY 09/01/2025

A phase 2 study shows adding everolimus to carboplatin significantly improves progression-free survival in advanced TNBC with manageable safety profile, indicating a potential new treatment avenue.